SCLY

Across TCGA pan-cancer cohorts, SCLY mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SCLY’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SCLY mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SCLY is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and PDAC are the cancer types where SCLY tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SCLY mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	−0.699	<.001	12	view →
HNSC	All	III,IV	−0.380	<.001	11	view →
PDAC	Female	All	−0.985	<.001	10	view →
COAD	Male	II,III,IV	−0.264	<.001	9	view →
LSCC	Male	II,III,IV	−0.188	<.001	6	view →
LUAD	Female	All	+0.150	.022	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SCLY–CCRCC

Open the CCRCC breakdown →